Physician profile
Marina V Ostroukhova
NPI 1043482706
$158,416.11
in general payments reported to CMS, 2019-2025
38 companies · $51K in 2025
The $51K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $6,602 · 2021: $10K · 2022: $14K · 2023: $25K · 2024: $29K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Food and Beverage: $14K · Travel and Lodging: $6,944 · Consulting Fee: $3,992 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,680.00 |
| Food and Beverage | $14,040.90 |
| Travel and Lodging | $6,943.78 |
| Consulting Fee | $3,992.00 |
| Education | $116.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $81,416.72 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $51,866.71 | 2019-2025 | Nucala, Trelegy Ellipta |
| Pharming Healthcare, INC. | $6,345.01 | 2019-2025 | Joenja, Ruconest |
| Regeneron Healthcare Solutions, INC. | $5,720.08 | 2019-2025 | Dupixent |
| Csl Behring | $1,880.83 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,585.41 | 2020-2025 | Takhzyro, Cuvitru, Entyvio |
| Genentech USA, INC. | $1,379.29 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $1,107.06 | 2021-2025 | Orladeyo |
| Genzyme Corporation | $998.63 | 2019-2025 | |
| Biocryst Pharmaceuticals, INC. | $875.00 | 2020 | |
| Abbvie INC. | $640.36 | 2022-2025 | |
| Pfizer INC. | $637.71 | 2020-2025 | |
| Blueprint Medicines Corporation | $530.68 | 2022-2025 | Ayvakit |
| Leo Pharma INC. | $475.59 | 2022-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $325.20 | 2021-2025 | Xembify |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Ostroukhova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.